$10.19
26.43% today
Nasdaq, Apr 25, 05:47 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$8.06
+2.02 33.44% 1M
-20.19 71.47% 6M
-17.19 68.08% YTD
-246.79 96.84% 1Y
-54,340.69 99.99% 3Y
-151,866.94 99.99% 5Y
-2,402,662,491.94 100.00% 10Y
Nasdaq, Closing price Thu, Apr 24 2025
+1.39 20.84%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Market capitalization $5.43m
Enterprise Value $35.66m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 3.05
P/S ratio (TTM) P/S ratio 0.46
P/B ratio (TTM) P/B ratio 0.58
Revenue growth (TTM) Revenue growth 19.75%
Revenue (TTM) Revenue $11.69m
EBIT (operating result TTM) EBIT $-30.83m
Cash position $8.00m
EPS (TTM) EPS $-233.19
P/E forward negative
P/S forward 0.21
EV/Sales forward 1.66
Short interest 7.79%
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

Buy
100%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
12 12
20% 20%
100%
- Direct Costs 4.31 4.31
5% 5%
37%
7.38 7.38
31% 31%
63%
- Selling and Administrative Expenses 19 19
4% 4%
165%
- Research and Development Expense 17 17
11% 11%
141%
-28 -28
10% 10%
-244%
- Depreciation and Amortization 2.36 2.36
1% 1%
20%
EBIT (Operating Income) EBIT -31 -31
9% 9%
-264%
Net Profit -38 -38
7% 7%
-329%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
8 days ago
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments f...
Neutral
Accesswire
10 days ago
The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup Jaguar planning to meet wit...
Neutral
Accesswire
17 days ago
Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow tr...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website www.jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today